Back to top

LACOG 0415 – APA in Prostate Cancer

  /    /  LACOG 0415 – APA in Prostate Cancer

Phase II randomized study of Abiraterone acetate plus ADT versus APALUTAMIDE versus Abiraterone and APALUTAMIDE in patients with advanced prostate cancer with non-castrate testosterone levels

Type of Study: Clinical Trial

Sponsor / Support: LACOG, Janssen

Primary Objectives: We aim to assess the activity, safety and patients reported outcome of ADT plus abiraterone, abiraterone plus APALUTAMIDE (a second-generation antiandrogen) or APALUTAMIDE alone in hormone naïve locally advanced or metastatic prostate cancer which ADT was indicated.

Design: This is a phase II, open label, randomized trial

Sample Size: 126 patients

Principal Investigator: Fernando Cotait Maluf

Countries LATAM: Brazil Identifier: NCT02867020